Drug Profile
AZ 04
Alternative Names: AZ-04; PDI-44Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Ache Laboratories
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for research development in Chronic-obstructive-pulmonary-disease in Brazil
- 03 Jun 2020 Research development in Chronic obstructive pulmonary disease is ongoing in Brazil (Ache Laboratories pipeline, June 2020)
- 03 Jun 2020 AZ 04 is available for licensing as of 03 Jun 2020. https://www.ache.com.br/